Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: =99.66%
Mitomycin C (Mitozytrex; Mutamycin; Ametycine) is an antineoplastic antibiotic drug that acts by inhibiting DNA synthesis, and has been approved to treat different cancers. Mitomycine C is an analog of methylazirinopyrroloindoledione that has been isolated from Streptomyces caespitosus and other Streptomyces type bacteria. By producing interstrand DNA cross-links, oxygen radicals, and alkylation of DNA, bioreduced mitomycin C inhibits the synthesis of new DNA.
Targets |
Traditional Cytotoxic Agents
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Human colon cancer cells, HT-29 and colon adenocarcinoma HCT116, are employed respectively. The number of viable cells present in the culture is indicated by the luminescent signal generated by the CellTiter-Glo Luminescent Cell Viability Assay, which measures ATP using a special, stable form of luciferase. After exposing the cells to varying concentrations of TRAIL for 12 hours, the cells are pretreated with 5 μM of mitomycin C for either 12 or 24 hours. After adding an equivalent volume (100 μL) of CellTiter-GloTM reagent, the mixture is carefully mixed on an orbital shaker for two minutes. After allowing the luminescent signal to stabilize for ten minutes at room temperature, the mixture is imaged using the Xenogen IVIS system to determine the viability of the cells.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C15H18N4O5
|
---|---|
Molecular Weight |
334.37
|
Exact Mass |
334.13
|
Elemental Analysis |
C, 53.89; H, 5.43; N, 16.76; O, 23.93
|
CAS # |
50-07-7
|
Appearance |
Black solid powder
|
SMILES |
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
|
InChi Key |
NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
InChi Code |
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
Chemical Name |
[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
|
Synonyms |
Ametycine; mitomycine C; mitomycinX. US trade names: Mitozytrex; Mutamycin. Foreign brand names: Ametycine; MitocinC; Mitolem; MitoMedac; Mutamycine. Abbreviations: MITC; MITO; MITOC; MTC; NCIC04706
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9907 mL | 14.9535 mL | 29.9070 mL | |
5 mM | 0.5981 mL | 2.9907 mL | 5.9814 mL | |
10 mM | 0.2991 mL | 1.4953 mL | 2.9907 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05243550 | Active Recruiting |
Drug: UGN-102 | Bladder Cancer Urothelial Carcinoma |
UroGen Pharma Ltd. | March 1, 2022 | Phase 3 |
NCT03018418 | Active Recruiting |
Radiation: Proton therapy Drug: Chemotherapy |
Anus Neoplasms | Jordan Kharofa | January 4, 2017 | Phase 2 |
NCT04230759 | Active Recruiting |
Drug: Chemotherapy Radiation: Radiation |
Anal Cancer Anal Carcinoma |
Goethe University | January 7, 2020 | Phase 2 |
NCT03348969 | Active Recruiting |
Drug: Mitomycin c | Bladder Cancer | Jørgen Bjerggaard Jensen | November 1, 2017 | Phase 4 |
NCT03658304 | Active Recruiting |
Drug: Mitomycin c | Urothelial Carcinoma | University of Florida | December 5, 2018 | Phase 2 |